State Street Corp Purchases 299,737 Shares of Johnson & Johnson $JNJ

State Street Corp increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,776,025 shares of the company’s stock after purchasing an additional 299,737 shares during the quarter. Johnson & Johnson makes up approximately 0.7% of State Street Corp’s holdings, making the stock its 23rd biggest holding. State Street Corp owned approximately 0.06% of Johnson & Johnson worth $33,975,097,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Security National Bank of Sioux City Iowa IA increased its holdings in Johnson & Johnson by 27.2% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 18,143 shares of the company’s stock valued at $4,608,000 after purchasing an additional 3,878 shares in the last quarter. Reynders McVeigh Capital Management LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. Reynders McVeigh Capital Management LLC now owns 76,513 shares of the company’s stock worth $19,432,000 after purchasing an additional 499 shares during the last quarter. Bullseye Investment Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $63,000. Talon Private Wealth LLC increased its stake in shares of Johnson & Johnson by 89.5% in the second quarter. Talon Private Wealth LLC now owns 10,588 shares of the company’s stock valued at $2,689,000 after buying an additional 5,002 shares in the last quarter. Finally, U S Wealth Group LLC. raised its holdings in shares of Johnson & Johnson by 15.1% in the second quarter. U S Wealth Group LLC. now owns 17,259 shares of the company’s stock valued at $4,383,000 after buying an additional 2,266 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. TD Cowen increased their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. The Goldman Sachs Group reissued a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Weiss Ratings raised shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Finally, Guggenheim upped their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $274.13.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by company insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Caplyta produced positive Phase 3 results in bipolar mania. J&J said the drug met its primary endpoint, significantly reducing manic symptoms versus placebo by Week 3, with improvement visible as early as Day 3. The result could expand Caplyta beyond its current indications and strengthen the strategic rationale for J&J’s $14.6 billion acquisition of Intra-Cellular Therapies. Regulatory approval and commercial execution remain necessary before the opportunity becomes revenue. Reuters Caplyta bipolar mania study
• Positive Sentiment: J&J received European approval for ICOTYDE in plaque psoriasis, adding another potential growth driver to its immunology portfolio and supporting expectations for continued pharmaceutical expansion. EU ICOTYDE approval
• Positive Sentiment: Plans to divest the DePuy Synthes orthopedics business are boosting optimism about a more focused J&J. Reports suggest the unit could be sold for roughly $20 billion, allowing J&J to reduce exposure to slower-growing operations, improve profitability and redeploy capital toward higher-growth pharmaceuticals. DePuy Synthes divestiture report
• Neutral Sentiment: The Caplyta news is promising but still carries development risk. J&J must obtain regulatory clearance, demonstrate durable benefits and convert the expanded indication into meaningful sales; the trial’s three-week duration does not yet establish longer-term commercial performance. Caplyta expansion path

Johnson & Johnson Trading Down 0.4%

Shares of NYSE JNJ traded down $1.06 during midday trading on Tuesday, reaching $268.41. 1,982,335 shares of the stock were exchanged, compared to its average volume of 8,022,697. Johnson & Johnson has a 12 month low of $174.83 and a 12 month high of $281.07. The company has a market capitalization of $646.83 billion, a price-to-earnings ratio of 31.08, a P/E/G ratio of 2.58 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The business has a 50-day simple moving average of $263.99 and a two-hundred day simple moving average of $246.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.